1. Home
  2. COEP vs LGL Comparison

COEP vs LGL Comparison

Compare COEP & LGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COEP
  • LGL
  • Stock Information
  • Founded
  • COEP 2017
  • LGL 1917
  • Country
  • COEP United States
  • LGL United States
  • Employees
  • COEP N/A
  • LGL N/A
  • Industry
  • COEP Biotechnology: Biological Products (No Diagnostic Substances)
  • LGL Industrial Machinery/Components
  • Sector
  • COEP Health Care
  • LGL Technology
  • Exchange
  • COEP Nasdaq
  • LGL Nasdaq
  • Market Cap
  • COEP 32.0M
  • LGL 35.6M
  • IPO Year
  • COEP N/A
  • LGL N/A
  • Fundamental
  • Price
  • COEP $9.15
  • LGL $6.54
  • Analyst Decision
  • COEP
  • LGL
  • Analyst Count
  • COEP 0
  • LGL 0
  • Target Price
  • COEP N/A
  • LGL N/A
  • AVG Volume (30 Days)
  • COEP 31.8K
  • LGL 3.6K
  • Earning Date
  • COEP 05-14-2025
  • LGL 05-15-2025
  • Dividend Yield
  • COEP N/A
  • LGL N/A
  • EPS Growth
  • COEP N/A
  • LGL 204.51
  • EPS
  • COEP N/A
  • LGL 0.08
  • Revenue
  • COEP $62,874.00
  • LGL $4,322,000.00
  • Revenue This Year
  • COEP N/A
  • LGL N/A
  • Revenue Next Year
  • COEP N/A
  • LGL N/A
  • P/E Ratio
  • COEP N/A
  • LGL $86.44
  • Revenue Growth
  • COEP N/A
  • LGL 20.66
  • 52 Week Low
  • COEP $2.31
  • LGL $4.91
  • 52 Week High
  • COEP $13.70
  • LGL $7.28
  • Technical
  • Relative Strength Index (RSI)
  • COEP 46.80
  • LGL 46.59
  • Support Level
  • COEP $8.95
  • LGL $6.45
  • Resistance Level
  • COEP $9.85
  • LGL $6.75
  • Average True Range (ATR)
  • COEP 0.64
  • LGL 0.22
  • MACD
  • COEP -0.02
  • LGL -0.01
  • Stochastic Oscillator
  • COEP 10.47
  • LGL 46.25

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

About LGL LGL Group Inc. (The)

LGL Group Inc is a holding company engaged in services, merchant investment and manufacturing business activities. The company has two reportable segments; Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.

Share on Social Networks: